<DOC>
	<DOCNO>NCT01857284</DOCNO>
	<brief_summary>Though ursodeoxycholate acid ( UDCA ) wellknown effective therapy PBC , clinical effectiveness UDCA may limit poor absorption extensive biotransformation . The hydrophilic bile acid tauroursodeoxycholate ( TUDCA ) active ingredient UDCA , approve state food drug administration China treatment cholesterol stone . So necessary verify efficacy safety TUDCA treatment adult primary biliary cirrhosis . In randomized , double-blinded , double-dummy , parallel-controlled multicenter clinical trial , detect proportion patient AKP decline 25 % primary outcome ; decline AKP , total bilirubin , GGT , ALT AST secondary outcome patient treat TUDCA UDCA 24 week .</brief_summary>
	<brief_title>Safety Efficacy Tauroursodeoxycholic Acid Versus Ursofalk Treatment Adult Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>write informed consent age 1870 year increase alkaline phosphatase 2 fold positive antimitochondrial antibody ( AMA ) presence antibody pyruvate dehydrogenase complex ( AMAM2 ) ；AMAnegative patient diagnose PBC histologic evidence . 1. patient treated UDCA , immunosuppressive medication within 3 month . 2. patient evidence extrahepatic biliary obstruction 3. patient coinfection HBV HCV 4. patient one following : 1 ) hemoglobin ( HB ) : &lt; 11 g/dl male , &lt; 10 g/dl female 2 ) white blood cell count &lt; 3000/mm3 3 ) neutrophile granulocyte &lt; 1500/mm3 4 ) platelet &lt; 50000/mm3 ; 5 ) serum albumin &lt; 3.3 g/dl 6 ) alanine aminotransferase ( ALT ) ≥10×ULN and/or aspartate aminotransferase ( ALT ) ≥10×ULN ; 7 ) ALT≥5×ULN and/or AST≥5×ULN coexist immunoglobulin G ( IgG ) ≥2×ULN ; 8 ) total bilirubin ≥4×ULN ; 9 ) prothrombin time ( PT ) prolong 3 second , PTA ≦60 % ; 10 ) creatinine ≥4×ULN . 5. patient evidence decompensated liver disease ( ascites , gastrointestinal bleeding , hepatic encephalopathy et al . ) 6. definitely diagnosed hepatocellular carcinoma ( HCC ) , probable HCC , AFP &gt; 100ng/ml.Patients AFP &gt; 2×ULN &lt; 100ng/ml retest 2 week later . 7 . Body Mass Index &gt; 28 kg/m2 8. drug alcohol abuse . 9. patient severe disease heart , lung , kidney , alimentary canal , neural system , autoimmune disease tumor 10. patient schedule organ transplantation ; 11. patient followup consider impossible 12. pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Tauroursodeoxycholic Acid</keyword>
	<keyword>Primary Biliary Cirrhosis</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>